{"drugs":["BabyBIG","Botulism Immune Globulin"],"mono":{"0":{"id":"928037-s-0","title":"Generic Names","mono":"Botulism Immune Globulin"},"1":{"id":"928037-s-1","title":"Dosing and Indications","sub":[{"id":"928037-s-1-4","title":"Adult Dosing","mono":"safety and efficacy not established in adults or geriatric patients "},{"id":"928037-s-1-5","title":"Pediatric Dosing","mono":"<ul><li>safety and efficacy not established in patients 1 year of age and older<\/li><li><b>Infant botulism, Caused by toxin type A or B:<\/b> less than 1 year of age, 1.5 mL\/kg (75 mg\/kg) IV as soon as diagnosis is made; start infusion at 0.5 mL\/kg\/hr (25 mg\/kg\/hr) and may increase to 1 mL\/kg\/hr (50 mg\/kg\/hr) after 15 min if no untoward reactions occur; do not exceed a rate of 1 mL\/kg\/hr<\/li><\/ul>"},{"id":"928037-s-1-6","title":"Dose Adjustments","mono":"<b>renal insufficiency, any degree of or at risk of:<\/b> administer at the minimum concentration and minimum rate of infusion; do not exceed recommended dose "},{"id":"928037-s-1-7","title":"Indications","mono":"<b>FDA-Labeled Indications<\/b><br\/>Infant botulism, Caused by toxin type A or B<br\/>"}]},"3":{"id":"928037-s-3","title":"Contraindications\/Warnings","sub":[{"id":"928037-s-3-9","title":"Contraindications","mono":"<ul><li>selective IgA deficiency<\/li><li>severe reaction to other human immunoglobulin preparations<\/li><\/ul>"},{"id":"928037-s-3-10","title":"Precautions","mono":"<ul><li>concomitant use with nephrotoxic drugs; increased risk of acute renal failure; monitoring recommended<\/li><li>diabetes mellitus; increased risk of acute renal failure; monitoring recommended<\/li><li>live virus vaccine use not recommended within 5 months after botulism immune globulin administration<\/li><li>paraproteinemia; increased risk of acute renal failure; monitoring recommended<\/li><li>renal insufficiency; increased risk of acute renal failure; monitoring recommended<\/li><li>sepsis; increased risk of acute renal failure; monitoring recommended<\/li><li>volume depletion; increased risk of acute renal failure; monitoring recommended<\/li><\/ul>"},{"id":"928037-s-3-11","title":"Pregnancy Category","mono":"Fetal risk cannot be ruled out. (TH)<br\/>"},{"id":"928037-s-3-12","title":"Breast Feeding","mono":"Micromedex: Infant risk cannot be ruled out.<br\/>"}]},"5":{"id":"928037-s-5","title":"Adverse Effects","mono":"<b>Common<\/b><ul><li><b>Cardiovascular:<\/b>Hypertension (2%)<\/li><li><b>Dermatologic:<\/b>Erythematous condition (up to 14%)<\/li><li><b>Endocrine metabolic:<\/b>Hyponatremia (5%)<\/li><li><b>Hematologic:<\/b>Anemia (5%)<\/li><li><b>Otic:<\/b>Otitis media (11%)<\/li><li><b>Renal:<\/b>Urinary tract infectious disease (2%)<\/li><li><b>Respiratory:<\/b>Pneumonia (11%)<\/li><\/ul><b>Serious<\/b><ul><li><b>Cardiovascular:<\/b>Hypotension<\/li><li><b>Immunologic:<\/b>Anaphylaxis<\/li><li><b>Neurologic:<\/b>Aseptic meningitis<\/li><li><b>Respiratory:<\/b>Respiratory arrest (2%)<\/li><\/ul>"},"6":{"id":"928037-s-6","title":"Drug Name Info","sub":{"0":{"id":"928037-s-6-17","title":"US Trade Names","mono":"BabyBIG<br\/>"},"2":{"id":"928037-s-6-19","title":"Class","mono":"Immune Serum<br\/>"},"3":{"id":"928037-s-6-20","title":"Regulatory Status","mono":"RX<br\/>"}}},"9":{"id":"928037-s-9","title":"Administration","mono":"<b>Intravenous<\/b><br\/><ul><li>reconstitute single-dose vial with 2 mL Sterile Water for Injection, USP<\/li><li>infusion should begin within 2 hours after reconstitution is complete and should be concluded within 4 hours of reconstitution<\/li><li>administer through a separate IV line; if not possible, infuse through a separate line containing Sodium Chloride and\/or Dextrose in Water 2.5% to 20%; use of an in-line or syringe-tip 18 micrometer filter is recommended<\/li><li>pre-dilution not recommended; if required, dilute no more than 1:2 with sodium chloride and\/or dextrose solutions<\/li><li>start infusion at 0.5 mL\/kg\/hr (25 mg\/kg\/hr); if well-tolerated after 15 minutes, may increase to 1 mL\/kg\/hr (50 mg\/kg\/hr)<\/li><li>do not exceed administration rate of 1 mL\/kg\/hr (50 mg\/kg\/hr)<\/li><li>slow or temporarily interrupt infusion for minor adverse reactions; discontinue infusion and administer epinephrine for anaphylaxis or hypotension.<\/li><\/ul>"},"10":{"id":"928037-s-10","title":"Monitoring","mono":"<ul><li>renal function tests and urinary output prior to administration<\/li><li>renal function tests during administration in patients at risk for acute renal failure<\/li><li>monitor for hypotension, anaphylaxis, or other allergic symptoms<\/li><\/ul>"},"13":{"id":"928037-s-13","title":"Clinical Teaching","mono":"<ul><li>Advise caregiver or parent to avoid vaccination of the child for at least 5 months after treatment.<\/li><li>This drug may cause erythema, hypotension, anemia, otitis media, or pneumonia.<\/li><\/ul>"}}}